Plasma Rich in Growth Factors for the Treatment of Dry Eye after LASIK Surgery.

Abstract

PURPOSE:

The aim of this study was to evaluate the use of plasma rich in growth factors (PRGF) eye drops in patients with dry eye disease after laser-assisted in situ keratomileusis (LASIK) surgery.

MATERIAL AND METHODS:

This is a longitudinal, retrospective, comparative, and descriptive study of 77 eyes of 42 patients with dry eye disease following LASIK surgery. This study was designed to evaluate the efficacy of PRGF treatment compared to conventional therapy (control group). Outcome measures including signs and symptoms of dry eye disease were evaluated before and after treatment. The percentage of change before and after treatment for each clinical variable measured was compared between both groups.

RESULTS:

There were 1-4 treatment cycles with PRGF eye drops (1 cycle = 6 weeks). Results showed a statistically significant improvement in the Ocular Surface Disease Index (38.12%), visual analogue scale scores for frequency (41.89%) and severity (42.47%), and the Schirmer test scores (88.98%) after PRGF treatment (p < 0.05). No adverse events were reported after PRGF treatment.

CONCLUSIONS:

These results suggest that PRGF eye drops are effective for the improvement of dry eye symptoms in patients who underwent LASIK surgery in comparison to the conventional therapy. The treatment with PRGF is an alternative for patients who suffer from postoperative dry eye.

• Authors: Ronald Mauricio Sanchez-Avila, Jesus Merayo-Lloves, Maria Laura Fernandez, Luis Alberto Rodriguez-Gutierrez, Nancy Jurado, Francisco Muruzabal, Gorka Orive, Eduardo Anitua
• Journal: Ophthalmic research (Ophthalmic Res) Vol. 60 Issue 2 Pg. 80-86 ( 2018) ISSN: 1423-0259 [Electronic] Switzerland
• PMID: 29886478 (Publication Type: Comparative Study, Journal Article)
• Copyright: © 2018 S. Karger AG, Basel.

Chemical References

• Intercellular Signaling Peptides and Proteins
• Ophthalmic Solutions

Topics

• Adult
• Aged
• Aged, 80 and over
• Cornea (drug effects)
• Dry Eye Syndromes (drug therapy, etiology)
• Female
• Humans
• Intercellular Signaling Peptides and Proteins (therapeutic use)
• Keratomileusis, Laser In Situ (adverse effects)
• Male
• Middle Aged
• Ophthalmic Solutions (therapeutic use)
• Plasma
• Postoperative Complications (drug therapy)
• Retrospective Studies
• Visual Acuity